In this context, research efforts have been devoted to understanding the mechanism by which mutations of the splicing factor SF3B1 affect BPS recognition, thus leading to aberrant splicing and to the outbreak of distinct hematological malignancies (Cretu et al., 2018). This evidence concerns the gene SF3B1 and hematologic disorder.